Skip to main content
. 2021 Jul 27;27(19):5299–5306. doi: 10.1158/1078-0432.CCR-21-0607

Table 2.

Association of tumor-specific MHC-II/HLA-DR expression with outcome to pembrolizumab and NAC or chemotherapy alone.

pCR RD
HLA-DR/DP/DQ/DX intensity units: ≥17,000 (RPPA-high) n (%) <17,000 (RPPA-low) n (%) ≥17,000 (RPPA-high) n (%) <17,000 (RPPA-low) n (%) OR (95% CI)≥17,000 (RPPA-high) χ2 P value (1-tailed)
All patients Paclitaxel (n = 87) 2 (2%) 11 (13%) 12 (14%) 62 (71%) 1.063 (0.23–5.3) 0.47
Paclitaxel + pembrolizumab (n = 66) 12 (18%) 17 (26%) 3 (2%) 34 (55%) 8 (1.938–28.42) 0.0007
HR+/HER2 Paclitaxel (n = 49) 2 (4%) 5 (10%) 7 (14%) 35 (71%) 2 (0.3381–10.37) 0.22
Paclitaxel + pembrolizumab (n = 40) 8 (20%) 4 (10%) 2 (5%) 26 (65%) 26 (4.253–136.3) <0.0001
TNBC Paclitaxel (n = 38) 0 (0%) 6 (16%) 5 (13%) 27 (71%) 0 (0.000–4.53) 0.15
Paclitaxel + pembrolizumab (n = 26) 4 (15%) 13 (50%) 1 (4%) 8 (31%) 2.46 (0.28–33.43) 0.22

Note: Values in bold are statistically significant.

HHS Vulnerability Disclosure